Matt Devalaraja

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

Paul M. Ridker, Matt Devalaraja, Florian M.M. Baeres et al. · The Lancet · 2021 · 596 citations

Inflammation, Anti-inflammatory, Cardiovascular Disease +10

The Clinical Significance of Interleukin-6 in Heart Failure: Results from the BIOSTAT-CHF Study

George Markousis‐Mavrogenis, Jasper Tromp, Wouter Ouwerkerk et al. · European Journal of Heart Failure · 2019 · 268 citations · Full text

Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Pablo E. Pérgola, Matt Devalaraja, Steven Fishbane et al. · Journal of the American Society of Nephrology · 2020 · 72 citations · Full text

Use of a Canine Model of Atopic Dermatitis to Investigate the Efficacy of a CCR4 Antagonist in Allergen-Induced Skin Inflammation in a Randomized Study

Clare Murray, Kim Ahrens, Matt Devalaraja et al. · Journal of Investigative Dermatology · 2015 · 23 citations

Inflammation, Drug Hypersensitivity, Allergy +11

Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts Study

Belinda Spoto, Rahul Kakkar, Larry Lo et al. · Journal of Clinical Medicine · 2019 · 23 citations · Full text